NASDAQ$SCPH
scPharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
scPharmaceuticals reported first quarter 2023 financial results, highlighted by FUROSCIX launch and revenue generation.
scPharmaceuticals announced the launch of FUROSCIX and reported $2.1 million in net FUROSCIX revenue for Q1 2023. The company ended the quarter with $116.1 million in cash, cash equivalents and short-term investments. Net loss for the quarter was $11.2 million.
- Launched and commercially available FUROSCIX on February 20, 2023.
- Generated net FUROSCIX revenue of $2.1 million in Q1 2023.
- Ended Q1 2023 with $116.1 million in cash, cash equivalents and short-term investments.
- Secured positive coverage and a preferred formulary decision by a top five national commercial health plan effective June 1, 2023.
Headline financials
Revenue & EPS history
scPharmaceuticals · Revenue · Quarterly
$2.06M
Revenue by segment
scPharmaceuticals · $2.1M total across 1 segment · Q1 2023
- FUROSCIX$2.1M—100.0%
Forward guidance
scPharmaceuticals is focused on expanding coverage and favorable formulary placement of FUROSCIX, aiming to increase the percentage of heart failure patients with access to a fixed-tier copay of $100 or less from the current 60% towards a goal of 75% or more. The company believes it is well-funded to execute its commercial plan and deliver FUROSCIX to patients.
Tailwinds
- Securing the broadest and most favorable coverage of FUROSCIX with both commercial and Medicare Part D payers.
- Recently notified by a top five national health plan that FUROSCIX would be placed in a preferred formulary status across all of its commercial plans effective June 1st.
- Working to increase the percentage of heart failure patients who have access to FUROSCIX through a fixed-tier copay of $100 or less, currently 60%, toward our goal of 75% or more.
- Well funded, with more than $116 million of cash, cash equivalents and investments as of March 31st.
- Ample resources to continue to execute on our commercial plan and deliver FUROSCIX to the heart failure patients who stand to benefit from this novel outpatient treatment alternative
Headwinds
- Risk of any unforeseen delays or setbacks in the commercialization of FUROSCIX.
- Risk of the ability of the FUROSCIX On-Body Infusor to appropriately deliver therapy.
- Risks related to manufacturing and quality assurances processes.
- Risk that global economic factors and uncertainties, including as a result of the COVID-19 pandemic, will impact the Company’s operations.
- The company reported a net loss of $11.2 million for the first quarter of 2023
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+3.8%
Avg return
Earnings day
+5.8%
Avg return
5 days after
+7.1%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+52.7%
Q4 2019
Best reaction
-14.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | -7.4% | -4.6% | +11.6% | |
| Q1 2025 | +27.4% | +45.1% | +74.8% | |
| Q4 2024 | -1.0% | -1.3% | -15.5% | |
| Q3 2024 | -14.5% | -14.8% | -18.6% | |
| Q2 2024 | +2.6% | +3.7% | +11.8% | |
| Q1 2024 | +5.1% | +10.6% | -6.9% | |
| Q4 2023 | -1.1% | +2.2% | -7.8% | |
| Q3 2023 | -8.4% | — | — | |
| Q2 2023 | +0.0% | — | — | |
| Q1 2023 | -0.6% | — | — | |
| Q4 2022 | +25.0% | — | — | |
| Q3 2022 | +7.3% | — | — | |
| Q2 2022 | +8.6% | — | — | |
| Q1 2022 | +7.7% | — | — | |
| Q4 2021 | +7.0% | — | — | |
| Q3 2021 | -10.1% | — | — | |
| Q2 2021 | +4.9% | — | — | |
| Q1 2021 | -5.3% | — | — | |
| Q4 2020 | -6.6% | — | — | |
| Q3 2020 | +2.0% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | -4.0% | — | — | |
| Q4 2019 | +52.7% | — | — | |
| Q3 2019 | -5.4% | — | — | |
| Q2 2019 | +10.1% | — | — | |
| Q1 2019 | +0.6% | — | — | |
| Q4 2018 | -4.8% | — | — | |
| Q3 2018 | +1.2% | — | — | |
| Q2 2018 | +2.9% | — | — | |
| Q1 2018 | +29.2% | — | — | |
| Q4 2017 | -6.7% | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro